Advertisement

Systemic Lupus Erythematosus in Adolescence and Young Adulthood

  • Lori B. TuckerEmail author
Chapter
Part of the In Clinical Practice book series (ICP)

Abstract

Systemic lupus erythematosus (SLE) is a chronic autoimmune condition, affecting multiple organ systems, often with waves of disease activity resulting in damage over many years. SLE begins in childhood and adolescence in approximately 20% of cases. Diagnosis of SLE requires clinicians to consider this diagnosis in adolescents and young adults (AYAs) with puzzling multisystem problems or new-onset nephritis. Care for the AYA with lupus requires a multidisciplinary approach, monitoring for impact of disease and therapy on AYA development and cardiovascular, neurologic, and bone health.

Keywords

Systemic lupus Adolescence Nephritis 

References

  1. 1.
    Barsalou J, Levy DM, Silverman ED. An update on childhood-onset systemic lupus erythematosus. Curr Opin Rheumatol. 2013;25:616–22.CrossRefGoogle Scholar
  2. 2.
    Levy DM, Kamphuis S. Systemic lupus in children and adolescents. Pediatr Clin N Am. 2012;59(2):345–64.CrossRefGoogle Scholar
  3. 3.
    Groot N, de Graeff N, Avcin T, Bader-Meunier B, Brogan P, Dolezalova P, et al. European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative. Ann Rheum Dis. 2017;76:1788–96.CrossRefGoogle Scholar
  4. 4.
    Hollander MC, Sage MJ, Geenler AJ, Pendl J, Avcin T, Espada G, et al. International consensus for provisions of quality-riven care in childhood-onset systemic lupus erythematosus. Arthritis Care Res. 2013;65(9):1416–23.CrossRefGoogle Scholar
  5. 5.
    Hiraki LT, Feldman CH, Liu J, Alarcon GS, Fischer MA, Winkelmayer WC, et al. Prevalence, incidence and demographics of systemic lupus erythematosus and lupus nephritis from 2000 to 2004 among children in the US medicaid beneficiary population. Arthritis Rheum. 2012;64(8):2669–76.CrossRefGoogle Scholar
  6. 6.
    Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.CrossRefGoogle Scholar
  7. 7.
    Petri M, Orbai AM, Alarcon GS, Gordon C, et al. Derivation and validation of systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677–86.CrossRefGoogle Scholar
  8. 8.
    Jones JT, Cunningham N, Kashikar-Zuck S, Brunner HI. Pain, fatigue, and psychosocial impact on health related quality of life in childhood-onset lupus. Arthritis Care Res. 2016;68(1):73–80.CrossRefGoogle Scholar
  9. 9.
    Tunnicliffe DJ, Singh-Grewal D, Chaitow J, Mackie F, Manolios N, Lin MW, et al. Lupus means sacrifices: perspectives of adolescents and young adults with systemic lupus erythematosus. Arthritis Care Res. 2016;68(6):828–37.CrossRefGoogle Scholar
  10. 10.
    Gordon C, Amissah-Arthur MB, Gayed M, Brown S, Bruce IN, D'Cruz D, et al. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology. 2018;57(1):e1–e45.CrossRefGoogle Scholar
  11. 11.
    Ting TV, Kudalkar D, Nelson S, Cortina S, Pendl J, Budhani S, et al. Usefulness of cellular text messaging for improving adherence among adolescents and young adults with systemic lupus erythematosus. J Rheumatol. 2012;39(1):174–9.CrossRefGoogle Scholar
  12. 12.
    Scalzi LV, Hollenbeak CS, Mascuilli E, Olsen N. Improvement of medication adherence in adolescents and young adults with SLE using web-based education with and without a social media intervention, a pilot study. Pediatr Rheumatol. 2018;16:18.CrossRefGoogle Scholar
  13. 13.
    Rotstein Grein I, Groot N, Lacerda MI, Wulffraat N, Pileggi G. HPV infection and vaccination in systemic lupus erythematosus patients: what we really should know. Pediatr Rheumatol. 2016;14:12.CrossRefGoogle Scholar
  14. 14.
    Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with systemic lupus erythematosus. NEJM. 2005;353:2550–8.CrossRefGoogle Scholar
  15. 15.
    Kyvernitakis I, Kostev K, Nassour T, Thomasius F, Hadji P. The impact of depot medroxyprogesterone acetate on fracture risk: a case-control study from the UK. Osteoporos Int. 2017;28(1):291–7.CrossRefGoogle Scholar
  16. 16.
    Brunner HI, Silva CA, Reiff A, Higgins G, Imundo L, Williams CB, et al. Randomized, double-blind dose escalation trial of triptorelin for ovary protection in childhood-onset systemic lupus erythematosus. Arthritis Rheum. 2015;67(5):1377–85.CrossRefGoogle Scholar
  17. 17.
    Caramaschi P, Biasis D, Dal Forno I, Adami S. Osteonecrosis in systemic lupus erythematosus: an early, frequent, and not always symptomatic complication. Autoimmune Diseases. 2012;2012:1–7.CrossRefGoogle Scholar
  18. 18.
    Schoenfeld SR, Kasturi S, Costenbader KH. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. Semin Arthritis Rheum. 2013;43:77–95.CrossRefGoogle Scholar
  19. 19.
    Sarkissian T, Beyene J, Feldman B, McCrindle B, Silverman ED. Longitudinal examination of lipid profiles in pediatric systemic lupus erythematosus. Arthritis Rheum. 2007;56(2):631–8.CrossRefGoogle Scholar
  20. 20.
    Schanberg LE, Sandborg C, Barnhart HX, Ardoin SP, Yow E, Evans GW, et al. Premature atherosclerosis in pediatric systemic lupus erythematosus: risk factors for increased carotid intima-media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohort. Arthritis Rheum. 2009;60(5):1496–507.CrossRefGoogle Scholar
  21. 21.
    Al-Obaidi M, Saunders D, Brown S, et al. Evaluation of magnetic resonance imaging abnormalities in juvenile onset neuropsychiatric systemic lupus erythematosus. Clin Rheumatol. 2016;35(10):2449–56.CrossRefGoogle Scholar
  22. 22.
    Popescu A, Kao AH. Neuropsychiatric systemic lupus erythematosus. Curr Neuropharmacol. 2011;9:449–57.CrossRefGoogle Scholar
  23. 23.
    Magro-Checa C, Zirkzee E, Huizinga TW, Steup-Beekman GM. Management of neuropsychiatrics systemic lupus erythematosus: current approaches and future perspectives. Drugs. 2016;76:459–83.CrossRefGoogle Scholar
  24. 24.
    Tektonidou MG, Lewandowski LB, Hu J, Dasgupta A, Ward MM. Survival in adults and children with systemic lupus erythematosus: a systemic review and Bayesian meta-analysis of studies from 1950 to 2016. Ann Rheum Dis. 2017;76(12):2009–16.CrossRefGoogle Scholar
  25. 25.
    Tucker LB, Uribe AG, Fernandez M, et al. Adolescent onset of lupus results in more aggressive disease and worse outcomes: a nested matched case-control study within LUMINA, a multiethnic US cohort (LUMINA LVII). Lupus. 2008;17:314–22.CrossRefGoogle Scholar
  26. 26.
    Lawson EF, Hersh AO, Trupin L, von Scheven E, Okumura MJ, Yazdany J, et al. Educational and vocational outcomes of adults with childhood onset and adult onset systemic lupus erythematosus: 9 years of follow up. Arthritis Care Res. 2014;66(5):717–24.CrossRefGoogle Scholar
  27. 27.
    Levy DM, Peschken CA, Tucker LB, Chedeville G, Huber AM, Pope J, et al. Health related quality of life in childhood-onset systemic lupus erythematosus is associated with ethnicity: results from a multiethnic multicenter Canadian cohort. Arthritis Care Res. 2014;66(12):1767–74.CrossRefGoogle Scholar
  28. 28.
    Mina R, Klein-Gitelman MS, Nelson S, Eberhard A, Higgins G, Singer NG, et al. Effects of obesity on health-related quality of life in juvenile-onset systemic lupus erythematosus. Lupus. 2015;24(2):191–7.CrossRefGoogle Scholar
  29. 29.
    Bernatsky S, Clarke AE, Niaki OZ, Labrecque J, Schanberg LE, Silverman ED, et al. Malignancy in pediatric-onset systemic lupus erythematosus. J Rheumatol. 2017;44(10):1484–6.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Division of RheumatologyBC Children’s Hospital, University of British ColumbiaVancouverCanada

Personalised recommendations